...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >T-cell and antibody response characterisation of a new recombinant pre-S1,pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration ofsuperior anti-SHBs antibody induction in responder mice
【24h】

T-cell and antibody response characterisation of a new recombinant pre-S1,pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration ofsuperior anti-SHBs antibody induction in responder mice

机译：一种新型重组的pre-S1，pre-S2和SHBs含抗原的乙型肝炎疫苗的T细胞和抗体应答表征;应答小鼠中超抗SHBs抗体诱导的实验证明

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The incidence of non-responders to hepatitis B (HB) virus SHBs antigen (Ag) vaccines has prompted the development of pre-S containing vaccines. The aim of this study was to characterise the murine immune responce to a novel recombinant particle (Hepagene) (Medeva pie) containing ple-S1, pre-S? and SHBsAg components. HepageneF induced potent in vitro spleen Tcell proliferative responses in both BALB/c (maximum stimulation index (SI)=38) and SWR/J (maximum SI=33) strains of mouse, following immunisation. High concentrations of interferon-gamma and low concentrations of interleukin-10 were detected in the media of spleen cells stimulated with Hepagene(TM). The anti-Hepagene(TM) antibody response was higher in SWR/J mice and alhydrogel adjuvant significantly improved the titres. Anti-pre-Si antibody was detected in both strains of mouse, whereas anti-pre-S2 antibody was only detected in SWR/J mice. IgG subclass analysis of the anti-Hepagene(TM) response revealed a Th2-type response in BALB/c mice and a mixed Th1/Th2 response in SWR/J mice. Hepagene(TM) induced higher anti-SHBs antibody responses than Engerix-B(R) (11097 and 1276 IU/ml, respectively) in BALB/c mice. Hepagene(TM) therefore, stimulates strong cellular and humoral immune responses in murine models. The high anti-SHBs antibody response suggests that Hepagene(TM) is an improved hepatitis B virus vaccine. (C) 1999 Elsevier Science Ltd. All rights reserved. [References: 26]
机译：对乙型肝炎（HB）病毒SHBs抗原（Ag）疫苗无反应的发生率促使人们开发了含pre-S的疫苗。这项研究的目的是鉴定鼠对含有ple-S1，pre-S？的新型重组颗粒（Hepagene）（Medeva pie）的免疫反应。和SHBsAg成分。免疫后，HepageneF在BALB / c（最大刺激指数（SI）= 38）和SWR / J（最大SI = 33）小鼠品系中诱导了有效的体外脾T细胞增殖反应。在被Hepagene TM刺激的脾细胞的培养基中检测到高浓度的干扰素-γ和低浓度的白介素-10。在SWR / J小鼠中，抗Hepagene（TM）抗体反应更高，并且水凝胶佐剂可显着提高滴度。在两种小鼠品系中均检测到抗pre-Si抗体，而仅在SWR / J小鼠中检测到抗pre-S2抗体。抗Hepagene（TM）反应的IgG亚类分析显示，BALB / c小鼠体内为Th2型反应，而SWR / J小鼠为Th1 / Th2混合反应。在BALB / c小鼠中，Hepagene（TM）诱导的抗SHBs抗体反应高于Engerix-B（分别为11097和1276 IU / ml）。因此，Hepagene TM在鼠模型中刺激强烈的细胞和体液免疫应答。高抗SHBs抗体反应表明Hepagene（TM）是一种改良的乙型肝炎病毒疫苗。 （C）1999 Elsevier ScienceLtd。保留所有权利。 [参考：26]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号